SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.84%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.59B
AUM Growth
+$1.59B
(-1.7%)
Cap. Flow
+$31.4M
Cap. Flow
% of AUM
1.98%
Top 10 Holdings %
Top 10 Hldgs %
62.27%
Holding
81
New
13
Increased
16
Reduced
16
Closed
16
Top Buys
| 1 |
Bolt Biotherapeutics
BOLT
|
$90.6M |
| 2 |
Eli Lilly
LLY
|
$26.8M |
| 3 |
NextCure
NXTC
|
$26.7M |
| 4 |
Align Technology
ALGN
|
$24.6M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$23.6M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$75.8M |
| 2 |
AbbVie
ABBV
|
$31.5M |
| 3 |
Amgen
AMGN
|
$31.3M |
| 4 |
United Therapeutics
UTHR
|
$22.2M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$14.4M |
Sector Composition
| 1 | Healthcare | 97.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $315M | 18.93% | 3,100,560 | – | – |
|
|
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $235M | 14.11% | 1,952,441 | – | – |
|
|
3
Bolt Biotherapeutics
BOLT
$9.85M
| $90.6M | 5.45% | +2,754,437 | New | +$90.6M |
|
|
4
Ascendis Pharma
ASND
$11.8B
| $67.3M | 4.04% | 521,923 -587,951 | -53% | -$75.8M |
|
5
Y-mAbs Therapeutics
YMAB
$388M
| $66.4M | 3.99% | 2,194,278 | – | – |
|
6
AstraZeneca
AZN
$248B
| $51.5M | 3.1% | 1,035,732 +193,132 | +23% | +$9.6M |
|
|
CMPI
7
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $43.8M | 2.63% | 3,606,707 | – | – |
|
8
Jazz Pharmaceuticals
JAZZ
$7.75B
| $42.1M | 2.53% | 255,928 +43,017 | +20% | +$7.07M |
|
|
INZY
9
DELISTED
Inozyme Pharma
INZY
| $40.2M | 2.41% | 2,028,308 | – | – |
|
|
10
United Therapeutics
UTHR
$13.8B
| $36M | 2.16% | 215,054 -132,847 | -38% | -$22.2M |
|
|
11
Eli Lilly
LLY
$657B
| $33.7M | 2.03% | 180,501 +143,592 | +389% | +$26.8M |
|
|
NCNA
12
NuCana
NCNA
$6.09M
| $27.9M | 1.68% | 5,599,999 | – | – |
|
13
Merus
MRUS
$4.98B
| $27.4M | 1.65% | 1,311,039 | – | – |
|
|
GRTX
14
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $27.2M | 1.64% | 3,083,712 | – | – |
|
|
15
NextCure
NXTC
$13.5M
| $26.7M | 1.61% | +2,671,856 | New | +$26.7M |
|
|
16
Align Technology
ALGN
$10.3B
| $24.6M | 1.48% | +45,500 | New | +$24.6M |
|
|
XLRN
17
DELISTED
Acceleron Pharma Inc.
XLRN
| $24.2M | 1.46% | 178,538 +141,850 | +387% | +$19.2M |
|
|
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $23.8M | 1.43% | 238,520 +89,583 | +60% | +$8.93M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $23.6M | 1.42% | +138,030 | New | +$23.6M |
|
|
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $22.2M | 1.34% | 655,001 -193,161 | -23% | -$6.55M |
|
21
PTC Therapeutics
PTCT
$3.92B
| $22.1M | 1.33% | 466,840 +150,362 | +48% | +$7.12M |
|
22
Insmed
INSM
$28.8B
| $21.1M | 1.27% | 618,950 +309,288 | +100% | +$10.5M |
|
|
AKUS
23
DELISTED
Akouos, Inc. Common Stock
AKUS
| $21M | 1.26% | 1,515,074 | – | – |
|
24
Exelixis
EXEL
$10.1B
| $19M | 1.14% | +839,181 | New | +$19M |
|
25
Protagonist Therapeutics
PTGX
$3.67B
| $17M | 1.02% | +654,900 | New | +$17M |
|